A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

This study is a prospective, multicenter, single arm clinical study. Thirty subjects who will have been diagnosed with locally advanced or metastatic non-small cell lung cancer with EGFR 21L858R mutation detected in lung cancer tissue or peripheral blood will be recruited and treated with anlotinib and aumolertinib. The efficacy will be evaluated according to the Solid Tumor Efficacy Evaluation Standard (RECIST 1.1), and evaluated every 6 to 8 weeks. The survival status and adverse reactions of the subjects will be recorded. The study will be terminated when the subjects experience disease pro

Trial Details

NCT ID

NCT06102928

Phase

NA

Sponsor

Kunming Medical University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Combined therapy of anlotinib and aumolertinib

Locations (sample)

• Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

• 1\) The patient voluntarily participated in this study and signed an informed consent form; 2) Age\>18 years old, both male and female; 3) Advanced…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →